TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Response to Glucagon During Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type II diabetes patients, female with non child-bearing potential~* T2DM diagnosis confirmed by C-peptide \>0.3nmol/L and no glutamic acid decarboxylate (GAD) antibodies at enrolment (screening)~* Treatment with metformin alone with a total daily dose not less than 1 000 mg. Stable glycaemic control indicated by unchanged treatment within 3 months prior to enrolment~Exclusion Criteria:~* History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease~* Signs of diabetic proliferative retinopathy or diabetic maculopathy, at screening or on an ophthalmological examination within 3 months from start of study~* Participating in another clinical study during the last 30 days prior to enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Diagnosis of a myelodysplastic syndrome~* Refractory anemia (RA)~* RA with ringed sideroblasts~* RA with excess blasts (RAEB). RAEB patients must have a bone marrow blast count of less than 20% and less than 5% blast forms on peripheral blood~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3~* Platelet count greater than 30,000/mm\^3 (without platelet transfusions)~* Hematocrit less than 30% (pretransfusion)~* Bilirubin less than 3 mg/dL~* Blood urea nitrogen (BUN) less than 40 mg/dL or Creatinine less than 2.0 mg/dL~* Prior epoetin alfa allowed provided dosage was less than 30,000 units per week for less than 1 month duration~* At least 1 month since prior erythropoietin~* At least 2 months since prior recombinant growth factor~* At least 2 months since prior chemotherapy for other malignancy or autoimmune disease~* At least 2 weeks since prior androgen or steroids for treatment of myelodysplastic syndromes~Exclusion Criteria:~* RAEB in transformation~* Chronic myelomonocytic leukemia~* Splenomegaly greater than 6 cm below the left costal margin or greater than 3 times normal size~* Uncontrolled hypertension~* Sensitivity to E. coli-derived proteins~* Sensitivity to epoetin alfa or any of its components (e.g., human albumin)~* Documented iron deficiency. If marrow iron stain is not available, the transferrin saturation must be greater than 20% or ferritin greater than 100 ng/dL~* Active infection or bleeding~* Other uncontrolled malignancy~* Pregnant or nursing. Fertile patients must use effective contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive Care (Type: ACTIVE_COMPARATOR): Patients received red cell and platelet transfusions for symptoms or to maintain hematocrit at or above 25% by volume. Patients who required transfusion support for symptomatic anemia prior to entering the study and who developed an increase in their transfusion requirement of \>= 50% shall cross over to the Erythropoietin treatment arm, after at least four months on the supportive therapy arm.
- Erythropoietin (Type: EXPERIMENTAL): Erythropoietin was administered at 150 units/kg subcutaneously every day. If patients stopped responding, they were subsequently treated with Erythropoietin (150 units/kg) and filgrastim and then Erythropoietin (300 units/kg) and filgrastim.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vorinostat in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children and adolescents (3-18 years) with relapsed or therapy-refractory solid tumor, lymphoma or leukemia following standard first-line or relapse protocols in pediatric oncology~* Diagnosis confirmed by one of the Pathological, Radiological or Study Reference Centers recognized by the GPOH~* No other simultaneous anti-neoplastic treatment or radiation during the study and 1 months before enrolment~* Sufficient general condition (Lansky Score \>50%)~* Life expectancy \> 3 months~* Liver enzymes (ALT or AST) \< 5x upper limit of normal reference value, bilirubin and creatinine \< 3x upper limit of normal reference value~* Solid tumors: leukocytes \> 2000/µl, thrombocytes \> 50.000/µl and adequate bone marrow function to permit evaluations of hematopoietic toxicity~* No CTC grade 3 or 4 toxicity from previous treatments~* Normal ECG~* Written informed consent of the legal representatives and the patient if the patient is able to understand the study situation and to give consent (must be available before enrolment in the trial)~* Women with childbearing potential agree to use adequate contraception or to abstain from heterosexual activity throughout the study, starting with Visit 1.~* Sexually active male patient agrees to use an adequate method of contraception for the duration of the study~* Solid tumors: measurable disease activity according to RECIST criteria~Exclusion Criteria:~* History of deep vein thrombosis or pulmonary embolism~* Pregnancy and lactation~* Patient with concomitant treatments and/or anti-neoplastic treatment such as chemotherapy, immune therapy, and differentiation therapy, other targeted therapy, radiation. The use of valproic acid as prior antiepileptic therapy is allowed with a 30-day washout period.~* Prior exposure to Histone Deacetylase Inhibitors~* Known active HBV, HCV or HIV infection~* Patient with concomitant treatments such as amber \[Hypericum perforatum\], plant extracts, vitamins, and other anti-oxidative compounds~* Participation in other clinical trials or observation period of competing trials, respectively~* Patient is unable to swallow vorinostat suspension or capsules~* Patient on coumarin-derivative anticoagulants~* Any other medication which could accentuate known dose-dependent adverse effects of the study drug, for instance bone marrow depression or QT-prolongation

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMS Augmented Exposure Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Criteria for a simple phobia: specific heights~Exclusion Criteria:~Objective tinnitus Involvement in psychiatric treatments Clinically relevant psychiatric comorbidity Clinically relevant unstable internal or neurological comorbidity History of or evidence of significant brain malformation or neoplasm, head injury Cerebral vascular events Neurodegenerative disorder affecting the brain or prior brain surgery Metal objects in and around body that can not be removed Pregnancy Alcohol or drug abuse history of seizures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Verum transcranial magnetic stimulation (TMS) (Type: EXPERIMENTAL): 10 Hz TMS over medial prefrontal cortex
- Sham transcranial magnetic stimulation (TMS) (Type: EXPERIMENTAL): 10 Hz sham TMS over medial prefrontal cortex

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who had received at least one dose of the study vaccine in the primary study~* Written informed consent will have been obtained from the subjects before the blood sampling visit of each year.

- Gender: ALL
- Minimum Age: 29 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Havrix Group (Type: EXPERIMENTAL): Subjects who received 2 doses of Havrix™ (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Havrix Group for data analyses during the long term follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patient with clinical and pathological diagnoses of severe cutaneous adverse drug reactions such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis or Durg reaction with eosinophilia and systemic symptoms.~2. Male or female patient aged more than 4 years.~3. Inform consent obtained.~Exclusion Criteria:~1. Pregnant or breastfeeding female.~2. Allergic to any anti-TNF-α biological product.~3. Active or latent tuberculosis confirmed with Chest X-ray.~4. Severe active infection and septicemia.~5. Active Hepatitis B or C carrier.~6. Suspected HIV carrier with CD4 count less than 200.~7. Patient with poor compliance or with safety concerns judged by investigator.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anti- TNF-a treatment (Type: EXPERIMENTAL): 1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~2. Fill out the case report form~3. Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~4. Etanercept administration:~The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
- control group (Type: ACTIVE_COMPARATOR): 1. Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~2. Fill out the case report form~3. Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~4. Drug administration:~The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with GAD as the principal or co-principal disorder~* Clinical Global Impression Score ≥ 4~* Hamilton Anxiety Rating Scale ≥ 18~* Hamilton Rating Scale for Depression ≤ 17~* Fluency in English~* Capacity to understand the nature of the study and willingness to sign informed consent form.~Exclusion Criteria:~* History of epilepsy or head trauma (LOC \> 5 minutes) within the past 6 months.~* Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis, or brain surgery.~* A review of patient medications by the study physician indicates an increased risk of seizure.~* An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency.~* Substance use disorder or PTSD within the past 6 months.~* Lifetime bipolar disorder, obsessive-compulsive disorder (OCD), psychotic disorder, mental retardation, or pervasive developmental disorder.~* Any psychotic features, including dementia or delirium. Concurrent psychotherapy and unwillingness to discontinue~* Medication change within past 3 months.~* Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months.~* Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study.~* Any contraindication for participation in MRI scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMS Therapy (Type: EXPERIMENTAL): TMS treatment
- TMS-Sham (Type: SHAM_COMPARATOR): This is a sham TMS condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Present parents diagnosed with periodontal health or generalized aggressive periodontitis~* Present between 6 and 12 years old~* Present good general health~Exclusion Criteria:~* The use of antibiotics or anti-inflammatories 6 months before the beginning of the study.~* Any Any change in the child's motor condition that interferes with the performance of appropriate hygiene procedures.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- G1: Triclosan/health children (Type: EXPERIMENTAL): Children from health parents will use the triclosan toothpaste for 45 days.
- G2: Placebo/health children (Type: PLACEBO_COMPARATOR): Children from health parents will use the placebo toothpaste for 45 days.
- G3: Triclosan/GAP children (Type: EXPERIMENTAL): Children from GAP parents will use the triclosan toothpaste for 45 days.
- G4: Placebo/GAP children (Type: PLACEBO_COMPARATOR): Children from GAP parents will use the placebo toothpaste for 45 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older with diagnosis for at least 12 months of moderate to severe plaque psoriasis covering at least 10% of body surface area~* A Psoriasis Area and Severity Index (PASI) score of 12 or greater~* Are considered to be candidates for systemic or light therapy~* Have no evidence of active or latent tuberculosis~Exclusion Criteria:~* Non-plaque or drug-induced forms of psoriasis~* Cannot discontinue current oral, injectible or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB)~* Any uncontrolled significant medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Treatment 10 mg BID (Type: EXPERIMENTAL): None
- Active Treatment 5 mg BID (Type: EXPERIMENTAL): None
- Placebo Treatment (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Immunocompromised due to hematologic malignancies, bone marrow failure syndromes, hematopoietic stem cell transplantation, solid organ transplantation, other conditions resulting in severe neutropenia, HIV infection, prolonged corticosteroid therapy, treatment with other immunosuppressive medications, or other immunocompromising conditions that place patients at risk for invasive fungal infections.~* Evidence of proven or probable invasive aspergillosis, by modified EORTC criteria~Exclusion Criteria:~* Concomitant other systemic antifungal agents are not permitted on study.~* Chronic invasive fungal infection, defined as signs/symptoms of invasive fungal infection present for \> 4 weeks preceding entry into study~* Prior systemic therapy of ≥ 4 days with any polyene anti-fungal agent within 14 days of study enrollment~* Prior systemic therapy of ≥ 4 days with non-polyenes for the current, documented IFI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1st cohort (Type: EXPERIMENTAL): 70mg caspofungin 1x/day
- 2nd cohort (Type: EXPERIMENTAL): 100mg caspofungin 1x/day
- 3rd cohort (Type: EXPERIMENTAL): 150mg caspofungin 1x/day
- 4th cohort (Type: EXPERIMENTAL): 200mg caspofungin 1x/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cutaneous Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers~* age above 18~Exclusion Criteria:~* any chronic disease~* any drug intake

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treprostinil (Type: EXPERIMENTAL): Treprostinil iontophoresis (250, 25 and 2.5 microM)
- Iloprost (Type: EXPERIMENTAL): Iloprost iontophoresis (200, 20 and 2 microM)
- NaCl 0.9% (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Minimally Invasive Surgical Treatment Versus Medical Management for Stroke Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of stroke and paroxysmal, persistent or permanent AF.~* Ischemic stroke or TIA with documented paroxysmal or persistent atrial fibrillation. A TIA will meet inclusion criteria as a sudden-onset focal neurological symptom or sign lasting at least 10 minutes but less than 24 hours with or without evidence of acute brain ischemia on diffusion weighted MRI imaging.~* Eligible symptoms INCLUDE hemiplegia or hemiparesis, monoplegia, or language disturbance other than isolated dysarthria.~* Symptoms that will NOT QUALIFY AS TIA INCLUDE transient monocular blindness in both eyes, dysarthria, vertigo,isolated sensory symptoms, confusion, memory loss, nonspecific complaints of dizziness, or syncope.~Exclusion Criteria:~* Recent stroke (\< 1 month).~* Age \< 18 or \> 80 years; Ejection Fraction \< 25%• Presence of left atrial appendage thrombus on CT or echocardiography~* Previous empyema or thoracic surgery, preventing access to the pulmonary veins via thoracoscopy.~* Left Atrial Diameter \> 55mm.~* Contraindication to anticoagulation with Coumadin.~* Mitral insufficiency (\> 2+)~* • • Contraindications to MRI~* •Artificial heart valve prosthesis~* Aneurysm clips~* Implanted drug infusion device or pump~* Any type of neurotranstimulator~* Any type of bone growth stimulator~* Cochlear implants or inner ear prosthesis~* Any intravascular coils, filters, or stents~* Shrapnel or bullets~* Other metallic implants or devices specify which~* Permanently tattooed eyeliner~* Are you pregnant or suspect to be pregnant?

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Minimally Invasive Surgery (Type: ACTIVE_COMPARATOR): Thumb sized incisions are made on each sides of the chest wall where instruments are placed in the chest to perform the surgery.
- Medical Therapy (Type: ACTIVE_COMPARATOR): Patients are treated with rhythm and rate control medications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete